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Population-Based Trends in High-Grade Cervical Lesions in the
Early Human Papillomavirus Vaccine Era in the United States
Susan Hariri, PhD1; Michelle L. Johnson, MPH1; Nancy M. Bennett, MD, MS2; Heidi M. Bauer, MD, MS, MPH3;
Ina U. Park, MD, MS3; Sean Schafer, MD4; Linda M. Niccolai, PhD5; Elizabeth R. Unger, MD, PhD6;
Lauri E. Markowitz, MD1; and HPV-IMPACT Working Group
BACKGROUND: Cervical intraepithelial neoplasia grade 2, 3, and adenocarcinoma in situ (CIN21) lesions can be monitored as early indi-
cators of human papillomavirus (HPV) vaccine impact. Changes to screening utilization will affect observed reductions in CIN21 rates
and complicate the interpretation of vaccine impact. METHODS: From 2008 to 2012, 9119 cases of CIN21 among 18- to 39-year-old
residents of catchment areas in California, Connecticut, New York, and Oregon were reported to the HPV-IMPACT Project, a sentinel
system for monitoring the population impact of HPV vaccine. Age-stratified CIN21 incidence rates were calculated for each catch-
ment. Annual cervical screening was estimated for California, New York, and Oregon catchments with administrative and survey data.
The Cochran-Armitage test was used to examine trends. RESULTS: From 2008 to 2012, the incidence of CIN21 significantly
decreased among 18- to 20-year-olds (California, from 94 to 5 per 100,000 women; Connecticut, from 450 to 57 per 100,000 women;
New York, from 299 to 43 per 100,000 women; and Oregon, from 202 to 37 per 100,000 women; Ptrend< .0001) and among 21- to
29-year-olds in Connecticut (from 762 to 589 per 100,000 women) and New York (from 770 to 465 per 100,000 women;
Ptrend< .001); rates did not differ among 30- to 39-year-olds. During the same period, screening rates also declined, with the largest
decreases among 18- to 20-year-olds (from 67% in Oregon to 88% in California) and with smaller declines among 21- to 29-year-olds
(13%-27%) and 30- to 39-year-olds (3%-21%). CONCLUSIONS: The declines in CIN21 detection in young women were likely due to
reduced screening but could also reflect the impact of vaccination. These data illustrate challenges in interpreting CIN21 ecologic
trends in the new era of cervical cancer prevention and emphasize the importance of information such as HPV types detected in
lesions to assess the impact of HPV vaccine on cervical precancers. Cancer 2015;121:2775-81. VC 2015 American Cancer Society.
KEYWORDS: cervical cancer screening, cervical intraepithelial neoplasia (CIN), cervical precancers, high-grade cervical lesions, human
papillomavirus (HPV), human papillomavirus vaccine effectiveness, human papillomavirus vaccines.
INTRODUCTION
Persistent infection with oncogenic types of human papillomavirus (HPV) can cause high-grade cervical intraepithelial ne-
oplasia (CIN) and adenocarcinoma in situ (CIN21); these asymptomatic lesions can, over decades, progress to invasive
cervical cancer if they are left untreated.1,2 Two vaccines against HPV 16 and HPV 18, types that are responsible for 70%
of cervical cancers and >50% of CIN21 lesions, are available in the United States, one since 2006.3 In clinical trials,
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both vaccines demonstrated high prophylactic efficacy
against CIN21 lesions, and this was the main endpoint
used for vaccine licensure.4,5
In countries with widespread cervical cancer screen-
ing programs, CIN21 lesions can be monitored as early
indicators of the population impact of HPV vaccination.
Less than a decade since the introduction of HPV vaccina-
tion, reductions in CIN21 have been observed in coun-
tries such as Australia and Denmark where vaccination
programs have included catch-up vaccine for older
women and have achieved high vaccination coverage
shortly after implementation.6-8 Because CIN21 is de-
tectable only through routine cervical cancer screening,
changes to screening utilization will contribute to
observed reductions in CIN21 rates and complicate the
interpretation of vaccine impact. To account for this,
studies in Denmark and Australia have examined CIN21
rates in vaccinated and unvaccinated individuals by link-
ing disease, screening, and immunization data across re-
gional or national population-based registries.6-8
Demonstrating vaccine impact on CIN21 is more
challenging in the United States because of incomplete
reporting of adolescent vaccination to state-based immu-
nization registries, a lack of national screening registries,
and, importantly, evolving cervical cancer screening prac-
tices. Over the past decade, the recommended age for ini-
tiating cervical cancer screening has been raised to 21
years, and screening intervals have been increased, particu-
larly if HPV-based cotesting is used.9 The objectives of
this ecologic study were to 1) describe trends in CIN21
diagnosis rates in different geographic areas in the United
States with population-based data from the first 5 years of
the HPV-IMPACT Project10 and 2) examine cervical can-
cer screening rates in the women residing in the HPV-
IMPACT catchment areas.
MATERIALS AND METHODS
System Description
HPV-IMPACT was established in 2008 to monitor the
impact of HPV vaccination on CIN21 through
population-based laboratory surveillance. The project is
an ongoing collaboration between the Centers for Disease
Control and Prevention and 5 sites in the Emerging Infec-
tions Program Network. Catchment areas include 8 con-
tiguous cities in northwest Alameda County, Calif.; New
Haven County, Conn.; Monroe County, NY; Davidson
County, Tenn.; and a contiguous region of Washington
and Multnomah Counties, Ore. (which includes the city
of Portland). The total population of women who were
18 years old or older ranged from 230,000 to 330,000 at
each participating site according to the 2010 US Census
data. This project was reviewed by the US Centers for
Disease Control, the Oregon Health Authority Public
Health Division, and the institutional review boards of
Yale University, University of California Berkeley, Uni-
versity of California San Francisco, Vanderbilt University,
Alameda County Medical Center, Kaiser Permanente,
Unity Health System, and Rochester General Hospital,
and it was determined to be exempt from institutional
review board approval because the activity constituted
routine disease surveillance for disease control program
and policy purposes. The project was approved by the
State of California Committee for the Protection of
Human Subjects. Informed consent was not required
from any reviewing/approving institution. All patient
records and information were anonymized and deidenti-
fied before analysis.
CIN21 Case Ascertainment
Local and commercial laboratories serving the catchment
areas reported cases of histologically confirmed CIN21
diagnosed in adult (18 years) female residents of the
areas. Cases were identified through electronic health re-
cord searches or manual chart reviews. Classification sys-
tems and nomenclature for high-grade cervical lesions
that were in use during the monitoring time period were
included in the search criteria to identify cases. Because
CIN21 is not a nationally notifiable condition, a variety
of methods were undertaken to enhance the completeness
of the reporting; these included the establishment of man-
dated reporting in Connecticut (since 2008) and Oregon
(since 2012). Laboratories that did not report before the
mandate in Oregon agreed to provide retrospective data
from 2008. At the time of this study, legal and logistical
challenges prevented the institution of mandates in New
York and California, but reporting was ensured through
the building of strong relationships with the laboratories
and through the engagement of community support. In
addition, laboratory audits were performed at all sites to
evaluate reporting completeness. The number of report-
ing laboratories ranged from 4 in New York to 29 in Con-
necticut; however, more than 80% of the cases were
reported by 3 to 5 laboratories in each area. Reports were
deduplicated within and between reporting laboratories.
Reported diagnoses were grouped by histologic grade
into CIN2, CIN2/3 (grade not discriminated), CIN3, and
adenocarcinoma in situ with or without CIN. CIN21
diagnoses reported for the same individual within 6months
of the initial diagnosis date were considered to be related to
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the same CIN21 lesion, and the case was classified accord-
ing to the highest grade diagnosis within the 6-month pe-
riod. For women diagnosed with CIN21 between the ages
of 18 and 39 years, attempts were made to collect the date
of birth, race/ethnicity, health insurance status, and clinical
and HPV vaccination history. Sources of data differed
according to the type of information collected and avail-
ability, and they included outpatient provider medical
records, administrative and claims databases, immuniza-
tion registries, and patient interviews.
Study Population
The analysis was restricted to participants aged 18 to 39
years who were diagnosed with CIN21 between January
2008 and December 2012 in 4 of 5 catchment areas with
complete reporting for all years: California, Connecticut,
New York, and Oregon. Tennessee was excluded from this
analysis because of incomplete reporting for some years.
Ages were categorized into 3 age groups: 18 to 20, 21 to 29,
and 30 to 39 years. Self-reported race/ethnicity was used to
classify women into non-Hispanic white, non-Hispanic
black, Hispanic, and Asian groups; all other reported races
were combined into an other category, and this field was
indicated as missing for those without race/ethnicity infor-
mation. The vaccination status among those who were age-
eligible for vaccination (ie, aged 11-26 years at some point
during the study period) was classified as vaccinated (receipt
of at least 1 dose), not vaccinated, or unknown.
Cervical Cancer Screening Estimation
Aggregate or individual-level data were used to estimate
cervical cancer screening rates among female residents
aged 18 to 39 years for 3 project sites: California, New
York, and Oregon. Screening estimates for the catchment
population were not available for Connecticut. In Califor-
nia and Oregon, a variety of data sources, including
national and state-based surveys and administrative data,
were used to calculate a weighted estimate of screening by
age group. Women in the catchment area were divided
into 2 groups based on insurance status (insured or unin-
sured), and annual screening rates were obtained for each
group with data from the American Community Survey
and the Behavioral Risk Factor Surveillance Survey to esti-
mate the relative proportions and the differences in
screening rates between the groups. The insured and unin-
sured groups were then combined to estimate overall an-
nual screening rates by age group (18-20, 21-29, and 30-
39 years), which were adjusted for insurance status.
New York obtained deidentified cervical cancer
screening reports from each of 3 local cytopathology
laboratories serving Monroe County, NY. Each report
was deduplicated within the laboratory and included the
patient’s age and the results of the first screen in a given
calendar year. Reports across the 3 laboratories were com-
bined and categorized into specified age groups. Screening
rates were estimated with 2010 US Census data.
CIN21 Incidence Estimation
CIN21 incidence was determined using the date of the
first diagnosis reported within a 6-month period. Any
subsequent reports from the same person during the 6
months succeeding the incident were excluded. Annual
CIN21 incidence rates were calculated with 2010 US
Census data. Age-adjusted and age-specific CIN21 inci-
dences were estimated for each catchment area. Incidence
rates are reported per 100,000 female population.
Percent changes and 95% confidence intervals were
calculated for the initial and final years. The Cochrane-
Armitage test for linear trends was used to examine the
statistical significance of CIN21 incidence trends. Two-
sided statistical tests were considered significant at the a
level of .05.
RESULTS
CIN21 Diagnosis by Population Characteristics
From 2008 to 2012, a total of 11,394 CIN21 diagno-
ses among adult women aged 18 years and older were
reported to 4 HPV-IMPACT catchment areas; 9119
(80.0%) were aged 18 to 39 years and are included in
this report. CIN2 was the most common histologic di-
agnosis reported overall (50.8%) and in all catchment
areas; the incidence ranged from 41.1% in California to
57.9% in Connecticut (Table 1). CIN3 constituted
30.9% of diagnoses overall and was highest in Califor-
nia (36.2%). Adenocarcinoma in situ, with or without
CIN, accounted for only 2.3% of diagnoses. The ma-
jority of CIN21 diagnoses (59.2%) occurred in women
aged 21 to 29 years; 18- to 20-year-olds represented
only 4.6% of all reported cases. Among the 81.9% with
known race/ethnicity, 61.1% were non-Hispanic white,
14.7% were non-Hispanic black, 15.9% were Hispanic,
and 4.8% were Asian. Private insurance was most com-
monly reported overall (66.2%), and only 3.5%
reported no insurance. The HPV vaccination status was
available for 2991 of 6299 women with CIN21
(47.5%) who were age-eligible for vaccination during
the analysis time period. The proportion of those for
whom the vaccination history was ascertained
ranged by site from 23.2% in California to 62.8% in
New York.
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CIN21 Incidence
Age-adjusted rates of newly diagnosed CIN21 per
100,000 significantly decreased between 2008 and 2012
in Connecticut (from 543 to 407) and New York (from
505 to 344; Ptrend< .0001). During the same time period,
there was a nonsignificant increase in the incidence of
CIN21 in California (from 277 to 293) and Oregon
(from 325 to 344).
Reported incidence rates varied across the 4 catchment
areas for every year included in the analysis (Fig. 1). For all
years, rates were highest in Connecticut, which was followed
by New York, Oregon, and California. The age-adjusted
incidence was 1.96 times as high in Connecticut versus the
rate in California in 2008, but by 2012, the incidence in
Connecticut was only 1.39 times that of California.
CIN21 incidence rates for the 4 catchment areas are
presented by age group and year in Table 2. There was a
sharp and consistent decrease among 18- to 20-year-old
women across all sites between 2008 and 2012; the
decrease in incidence ranged from 82% in Oregon to
94% in California (Ptrend< .0001 for all areas). Incidence
trends were not consistent across catchment areas in the
older age groups in the same 5-year period. In the 21- to
29-year-old group, the CIN21 incidence significantly
decreased by 40% in New York and 23% in Connecticut
(P< .001) but increased slightly in Oregon (12%; 95%
confidence interval, 26% to 34%) and California (13%;
95% confidence interval, 27% to 37%). Among those
aged 30 to 39 years, incidence rates did not change signifi-
cantly in any of the catchment areas.
Trends in CIN21 Diagnosis and Screening
Utilization
Figure 2 displays annual CIN21 incidence and screening
rates by age group in the 3 catchment areas for which
screening rates could be estimated. Among 18- to 20-
year-olds, both CIN21 and screening rates decreased sub-
stantially in all catchment areas; screening rates decreased
TABLE 1. Selected Characteristics Among Women Aged 18 to 39 Years Who Were Diagnosed With CIN21
(HPV-IMPACT, 2008-2012)
Characteristic
Total
(n5 9119)
California
(n5 1748)
Connecticut
(n5 2971)
New York
(n5 2301)
Oregon
(n52099)
n % n % n % n % n %
Diagnosis
CIN2 4637 50.8 719 41.1 1720 57.9 1155 50.2 1043 49.7
CIN2/3 1452 15.9 363 20.8 357 12.0 413 17.9 319 15.2
CIN3 2819 30.9 632 36.2 860 28.9 667 29.0 660 31.4
AIS6CIN 211 2.3 34 1.9 34 1.1 66 2.9 77 3.7
Age
18-20 y 417 4.6 34 1.9 173 5.8 150 6.5 60 2.9
21-29 y 5400 59.2 937 53.6 1782 60.0 1468 63.8 1213 57.8
30-39 y 3302 36.2 777 44.5 1016 34.2 683 29.7 826 39.4
Race/ethnicity
Non-Hispanic white 4564 61.1 437 34.2 1419 58.1 1504 69.7 1204 75.7
Non-Hispanic black 1097 14.7 258 20.2 379 15.5 389 18.0 71 4.5
Hispanic 1185 15.9 329 25.8 525 21.5 185 8.6 146 9.2
Asian 356 4.8 193 15.1 49 2.0 43 2.0 71 4.5
Other 267 3.6 60 4.7 71 2.9 37 1.7 99 6.2
Missing 1650 — 471 — 528 — 143 — 508 —
Insurance
Private 5009 66.2 1039 70.9 1615 59.6 1324 68.1 1031 71.3
Publica 2037 26.9 402 27.4 956 35.3 471 24.2 208 14.4
Uninsuredb 267 3.5 13 0.9 88 3.2 56 2.9 110 7.6
Other 251 3.3 12 0.8 50 1.8 93 4.8 96 6.6
Missing 1555 — 282 — 262 — 357 — 654 —
Vaccination statusc
Vaccinated (1dose) 1452 23.1 127 11.7 555 26.4 568 33.0 202 14.5
Not vaccinated 1539 24.4 125 11.5 672 32.0 513 29.8 229 16.5
Unknown 3308 52.5 834 76.8 875 41.6 641 37.2 958 69.0
Not age-eligible 2820 — 662 — 869 — 579 — 710 —
Abbreviations: CIN21, cervical intraepithelial neoplasia grade 2, 3, and adenocarcinoma in situ; AIS, adenocarcinoma in situ; CIN, cervical intraepithelial neo-
plasia (numbers following “CIN” indicate the grade).
a Includes Medicaid (state assistance), Medicare, Indian Health Services, and Military/Veterans Administration.
b Includes documented self-pay or no coverage.
c Excludes those who were not eligible for vaccination because of age.
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67% in Oregon, 80% in New York, and 88% in Califor-
nia. Although the proportion of women screened in this
age group differed across catchment areas in the first year
of the study (from 41% in New York to 15% in Oregon),
screening rates declined to less than 10% in all areas by
2012, with the steepest decline occurring between 2009
and 2010. Overall CIN21 rate reductions exceeded esti-
mated declines in screening in this age group by 7% in
California, 5% in New York, and 15% in Oregon.
Screening rates decreased among women aged 21 to
29 years during the same time period, but to a smaller
degree. Relative decreases were 13% in Oregon, 26% in
New York, and 27% in California. In New York, there was
a corresponding and larger decline (40%) in the CIN21
incidence during the 5-year period. No CIN21 decreases
were observed in California or Oregon in this age group. In
the 30- to 39-year-old age group, there were inconsistent
changes in both CIN21 and screening rates. Overall,
screening decreased in all 3 catchment areas (3% in Califor-
nia, 18% in New York, and 21% in Oregon), whereas the
CIN21 incidence remained largely unchanged.
DISCUSSION
This population-based study describes the CIN21 inci-
dence in women across multiple geographic areas in the
United States and examines CIN21 incidence trends in
the first few years since the introduction of HPV vaccine.
We found striking differences in the baseline incidence of
CIN21 diagnoses across the 4 catchment areas. In the
first year of the study, the CIN21 burden in Connecticut
and New York was approximately twice that in Oregon
and California. Site differences diminished over the next 4
years as CIN21 rates significantly decreased in Connecti-
cut and New York but remained the same or slightly
increased in the other 2 catchment areas. Differences in
screening utilization among health care providers may be
partially responsible for the large geographic variability in
CIN21 rates. California and Oregon, areas with the low-
est CIN21 incidence and lower screening rates, tended to
have higher population enrollment in managed care
Figure 1. Age-adjusted CIN21 incidence (per 100,000)
among adult women aged 18 to 39 years by catchment area
and year (HPV-IMPACT, 2008-2012). *Rates were age-
adjusted to the 2010 US Census female population in 5-year
age groups (18-19, 20-24, 25-29, 30-34, and 35-39 years).
CIN21 indicates cervical intraepithelial neoplasia grade 2, 3,
and adenocarcinoma in situ.
TABLE 2. Incidence of CIN21 (per 100,000) by Age Group, Year, and Catchment Area (HPV-IMPACT, 2008-
2012)
Age
2008 2009 2010 2011 2012
% Change (2008-2012):
% (95% Confidence Interval)n Rate n Rate n Rate n Rate n Rate
18-20 y
California 18 94 10 52 3 16 2 10 1 5 294 (299, 258)
Connecticut 87 450 39 202 22 114 14 72 11 57 287 (293, 276)
New York 56 299 42 224 32 171 12 64 8 43 286 (293, 270)
Oregon 22 202 20 183 10 92 4 37 4 37 282 (294, 247)
21-29 y
California 192 348 173 314 176 319 180 326 216 392 13 (27, 37)
Connecticut 397 762 367 704 342 656 369 708 307 589 223 (233, 210)
New York 363 770 350 743 276 586 260 552 219 465 240 (249, 229)
Oregon 232 447 252 486 237 457 232 447 260 501 12 (26, 34)
30-39 y
California 160 270 153 258 133 224 157 265 174 293 9 (212, 35)
Connecticut 198 368 204 379 212 394 217 403 185 343 27 (224, 14)
New York 142 321 146 330 122 276 129 291 144 325 1 (220, 28)
Oregon 137 241 180 317 163 287 187 330 159 280 16 (28, 46)
Abbreviation: CIN21, cervical intraepithelial neoplasia grade 2, 3, and adenocarcinoma in situ.
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organizations, which were among the first to implement
new recommendations to extend screening intervals.9 The
gradual adoption of new screening guidelines by a wider
array of providers may explain the narrowing gap in rates
and larger declines in Connecticut and New York, where
traditional fee-for-service health systems predominated.
Another possible reason for the observed variability in
CIN21 incidence across sites could be differences in popu-
lation characteristics such as sexual behaviors and smoking,
which may differentially influence the risk for CIN21 in
these populations. Finally, differences in vaccination cover-
age may also play a role, although this is unlikely because
the greatest variability in incidence was in the first year
when few adult women with CIN21 would have been vac-
cinated, and site differences diminished over time as vacci-
nation coverage increased in this population.
We found a dramatic and consistent decrease in
CIN21 incidence in all catchment areas among 18- to
20-year-old women. By 2012, CIN21 diagnoses in this
age group had declined to 10 or fewer cases per 100,000
at all 4 sites. The observed declines in this age group were
likely due to wide-scale implementation of new guidelines
that recommend cervical cancer screening begin at the age
of 21 years. This is reflected in the substantial decrease in
cervical cancer screening that we found in this age group
during the same time period. However, the larger
decreases in CIN21 incidence with respect to declines in
screening suggest the possible impact of the vaccine on
reducing the true burden of CIN21 in this age group.
Trends in CIN21 rates in the older age groups were
inconsistent and more difficult to interpret. In particular,
we did not observe any decreases in CIN21 incidence in
the 20- to 29-year-age groups in California andOregon de-
spite the sustained declining trends in screening. An analy-
sis of more years of data is ongoing to determine any
emerging trends. The impact of the vaccine on CIN21
trends in this age group should become clearer over time as
more women in this age group receive HPV vaccine at
younger ages. However, decreases in the measured inci-
dence due to vaccination may be confounded by continued
changes in screening practices, such as the recent approval
of an HPV-based test for the primary screening of women
who are 25 years old or older. Among women aged 30 to
39 years, CIN21 rates were similarly inconsistent with no
discernible trends over the 5-year study period.
This analysis demonstrates the challenges in examin-
ing the ecologic effect of HPV vaccination on CIN21 inci-
dence trends during a time of concurrent changes to
screening recommendations, even in geographically well-
defined populations. Although our data suggest that less
screening in the youngest age group likely had the largest
impact on the observed declines in CIN21 rates, some of
the observed decreases may be attributable to vaccination.
Figure 2. CIN21 incidence (per 100,000 women) and propor-
tions screened by age group, year, and catchment area
(HPV-IMPACT, 2008-2012). CIN indicates cervical intraepithe-
lial neoplasia; CIN21, cervical intraepithelial neoplasia grade
2, 3, and adenocarcinoma in situ.
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However, it was not possible to quantify the relative contri-
bution of vaccination in these populations. Although a
complete and accurate vaccination history was not obtain-
able for the majority of this study population, national sur-
vey data indicate that self-reported HPV vaccination
coverage (1 dose) in women aged 19 to 26 years was low
during our study period and ranged from 11.6% in 2008
to 34.5% in 2012.11
To assist with the interpretation of observed CIN21
trends, we identified all available data sources with which
age-stratified annual screening rates in the catchment popu-
lation could be estimated. However, there were insufficient
data to allow estimation in one project area, and the use of
disparate data sources and estimation methodologies pre-
vented valid comparisons across the other 3 areas. Despite
these limitations, the fact that our findings were similar to
results obtained from the only population-based screening
registry in the United States is reassuring.12 In that study,
Cuzick et al12 found a significant 61% decrease in screening
in females aged 15 to 20 years from 22.4% in 2008 to 8.7%
in 2011. Finally, changes to CIN21 terminology and cod-
ing that occurred during the study period may have also
affected the completeness of the reporting. However, exten-
sive audits of reporting laboratories using broad search crite-
ria did not suggest differential or underreporting over time.
To our knowledge, this is the first examination of
trends in CIN21 diagnosis in multiple populations of US
women in the new era of cervical cancer prevention. These
results demonstrate large and uniform reductions in the
CIN21 incidence in young women aged 18 to 20 years as
well as more variable declines in women aged 20 to 29
years, which may be due to a combination of new screen-
ing guidelines and HPV vaccine introduction. Impor-
tantly, our data illustrate the challenges in assessing HPV
vaccine impact on cervical precancers in the United States
and emphasize the importance of additional information
such as the types of HPV detected in these lesions to assist
in this determination.13
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